Science Explorer Back to mapMap

Most cited papers from Fate Therapeutics (United States)

What are the most cited papers from Fate Therapeutics (United States)?

The most cited paper from Fate Therapeutics (United States) is "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations" (Alexander Edward Dela Cruz Drilon et al., 2018), with 489 citations. Next come "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies" (412) and "Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?" (252).

Showing 50 of 60 papers. Every paper with more than 24 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Alexander Edward Dela Cruz Drilon et al. · Cancer Discovery 9 Aug 2018 489
2 Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies David T. Rodgers, Magdalena Mazagova, Eric N. Hampton et al. · Proceedings of the National Academy of Sciences Open access 12 Jan 2016 412
3 Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Stephanie K Venn-Watson, Rick Lumpkin, Edward A. Dennis · Scientific Reports Open access 18 May 2020 252
4 iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy Frank M. Cichocki et al. · Science Translational Medicine Open access 4 Nov 2020 250
5 Additional support for schizophrenia linkage on chromosomes 6 and 8: A multicenter study Dieter B. Wildenauer et al. · American Journal of Medical Genetics 127 authors 22 Nov 1996 186
6 MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes Mark D. Erion, Paul D. van Poelje, Qun Dang et al. · Proceedings of the National Academy of Sciences Open access 23 May 2005 164
7 Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy Karrune V. Woan et al. · Cell stem cell Open access 14 Sep 2021 163
8 Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology Amy Kathleen LeBlanc, Matthew Breen, Peter L. Choyke et al. · Science Translational Medicine Open access 3 Feb 2016 151
9 GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity Frank M. Cichocki et al. · Cancer Research Open access 8 Aug 2017 147
10 Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma Timothy Francis Cloughesy et al. · JAMA Oncology Open access 29 Oct 2020 145
11 Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells Michelle Sætersmoen, Quirin Hammer, Bahram Bob Valamehr et al. · Seminars in Immunopathology Open access 25 Oct 2018 142
12 Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial Armin Ghobadi, Veronika Bachanová, Krish Patel et al. · The Lancet Open access 2025 137
13 A polymorphism in the 5′ untranslated region of the human ob gene is associated with low leptin levels Jörg Hager, Karine Clément, Stephan Francke et al. · International Journal of Obesity Mar 1998 128
14 Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim et al. · Clinical Cancer Research Open access 13 Apr 2020 121
15 Myogenic Differentiation of Muscular Dystrophy-Specific Induced Pluripotent Stem Cells for Use in Drug Discovery Ramzey Abujarour, Monica H. Bennett, Bahram Bob Valamehr et al. · Stem Cells Translational Medicine Open access 6 Jan 2014 118
16 Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial Jeffrey S. Miller et al. · Nature Medicine 31 Jan 2022 113
17 Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping Herman Netskar, Aline Pfefferle, Jodie P. Goodridge et al. · Nature Immunology Open access 2 Jul 2024 98
18 Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction Marc A. M. Simon, Rebecca R. Vanderpool, Mehdi syed Nouraie et al. · JCI Insight Open access 2 Nov 2016 90
19 Novel oxysterols have pro‐osteogenic and anti‐adipogenic effects in vitro and induce spinal fusion in vivo Jared S. Johnson, Vicente Meliton, Woo Kyun Kim et al. · Journal of Cellular Biochemistry Open access 26 Feb 2011 89
20 Guide Swap enables genome-scale pooled CRISPR–Cas9 screening in human primary cells Pamela Y. Ting et al. · Nature Methods 2 Oct 2018 87
21 Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia Frank M. Cichocki, Jodie P. Goodridge, Ryan Bjordahl et al. · Blood Open access 2 Aug 2022 85
22 Axin Pathway Activity Regulates in Vivo pY654-β-catenin Accumulation and Pulmonary Fibrosis Arnau Ulsamer, Ying Wei, Kevin K. Kim et al. · Journal of Biological Chemistry Open access 28 Dec 2011 85
23 Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma Frank M. Cichocki et al. · Nature Communications Open access 29 Nov 2022 81
24 Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours Jeffrey R. Infante, Ronald Lee Korn, Lee S. Rosen et al. · British Journal of Cancer Open access 26 Sep 2017 80
25 A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs Bahram Bob Valamehr, Ramzey Abujarour, Megan Robinson et al. · Scientific Reports Open access 6 Jan 2012 77
26 Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells Sjoukje J. C. van der Stegen, Pieter L. Lindenbergh, Roseanna Maria Petrovic et al. · Nature Biomedical Engineering Open access 8 Aug 2022 75
27 The Virome of Cerebrospinal Fluid: Viruses Where We Once Thought There Were None Chandrabali Ghose, Melissa Ly, Leila K. Schwanemann et al. · Frontiers in Microbiology Open access 6 Sep 2019 69
28 Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia Alvaro Haroun-Izquierdo et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2022 68
29 Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies Robyn L. Stanfield, Ian A. Wilson, Vaughn V. Smider · Science Immunology Open access 14 Jul 2016 67
30 Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment Péter Márton Szabó, Amir Vajdi, Namit Kumar et al. · Scientific Reports Open access 21 Feb 2023 63
31 Optimized Surface Markers for the Prospective Isolation of High-Quality hiPSCs using Flow Cytometry Selection Ramzey Abujarour, Bahram Bob Valamehr, Megan Robinson et al. · Scientific Reports Open access 31 Jan 2013 58
32 iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis Jibin Guan, Hong Guo, Tang Tang et al. · Advanced Functional Materials Open access 10 Apr 2021 57
33 Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma Binod Dhakal, Jesús G. Berdeja, Tara B. Gregory et al. · Blood 15 Nov 2022 56
34 Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model Naoya Uchida et al. · Nature Communications Open access 12 Oct 2023 54
35 A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice Asim Kumar Saha, Sharon L. Hyzy, Tahirih L. Lamothe et al. · Blood Open access 5 Jan 2022 51
36 Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity Aline Pfefferle, Bénédikt Jacobs, Herman Netskar et al. · Cell Reports Open access Nov 2019 51
37 Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies Amitkumar Mehta, Umar Farooq, Andy Chen et al. · Blood 15 Nov 2022 50
38 Innate inflammation drives NK cell activation to impair Treg activity Joseph W. Dean, Leeana D. Peters, Christopher A. Fuhrman et al. · Journal of Autoimmunity Open access 6 Feb 2020 49
39 Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells Darja Karpova et al. · Journal of Clinical Investigation Open access 14 May 2019 49
40 Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia Emily Chiu, Martin Felices, Frank M. Cichocki et al. · Molecular Therapy Open access 24 Jun 2021 47
41 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter et al. · British Journal of Pharmacology Open access 18 May 2015 47
42 Structural analysis of an HIV‐1 protease I47A mutant resistant to the protease inhibitor lopinavir Ron M. Kagan, Mark D. Shenderovich, Peter N.R. Heseltine et al. · Protein Science Open access 4 Jun 2005 46
43 Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart Mohammad Abdul‐Ghani, Colin M. Suen, Baohua Jiang et al. · Cell Research Open access 8 Aug 2017 45
44 Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency Maria Carmina Castiello, Marita Bosticardo, Nicolò Sacchetti et al. · Journal of Allergy and Clinical Immunology Open access 5 May 2020 42
45 Developing Defined Culture Systems for Human Pluripotent Stem Cells Bahram Bob Valamehr, Hideaki Tsutsui, Chih‐Ming Ho et al. · Regenerative Medicine Open access Sep 2011 41
46 Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function Mingchun Gao, Hamed Bayat, David M. Roth et al. · Cardiovascular Research 21 Oct 2002 41
47 Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies Quirin Hammer, Karlo Perica, Rina M. Mbofung et al. · Cell stem cell Open access 8 Jul 2024 40
48 A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma Marco Galasso, Paola Dama, Maurizio Previati et al. · Genome Medicine Open access Oct 2014 37
49 Structure‐based phenotyping predicts HIV‐1 protease inhibitor resistance Mark D. Shenderovich, Ron M. Kagan, Peter N.R. Heseltine et al. · Protein Science Open access Aug 2003 34
50 Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning Meera A. Srikanthan, Olivier Humbert, Kevin G. Haworth et al. · Molecular Therapy — Methods & Clinical Development Open access 7 Feb 2020 33

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.